These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 11920496

  • 21. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis.
    Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D.
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4465-73. PubMed ID: 15886238
    [Abstract] [Full Text] [Related]

  • 22. Antitumor effects of somatostatin analogs in neuroendocrine tumors.
    Sidéris L, Dubé P, Rinke A.
    Oncologist; 2012 Aug; 17(6):747-55. PubMed ID: 22628056
    [Abstract] [Full Text] [Related]

  • 23. Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs.
    Debono M, Hon LQ, Bax N, Blakeborough A, Newell-Price J.
    J Clin Endocrinol Metab; 2008 May; 93(5):1860-4. PubMed ID: 18303072
    [Abstract] [Full Text] [Related]

  • 24. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A, Dogliotti L, Mosca A, Tarabuzzi R, Torta M, Mari M, Gorzegno G, Fontana D, Angeli A.
    Prostate; 2001 May 15; 47(3):205-11. PubMed ID: 11351350
    [Abstract] [Full Text] [Related]

  • 25. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs.
    Fjällskog ML, Sundin A, Westlin JE, Oberg K, Janson ET, Eriksson B.
    Med Oncol; 2002 May 15; 19(1):35-42. PubMed ID: 12025889
    [Abstract] [Full Text] [Related]

  • 26. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
    Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K.
    Acta Oncol; 1997 May 15; 36(6):607-14. PubMed ID: 9408151
    [Abstract] [Full Text] [Related]

  • 27. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL, Ferone D, Albertelli M, Pavlakis N, Segelov E, Singh S.
    Endocrine; 2017 Sep 15; 57(3):366-375. PubMed ID: 28726183
    [Abstract] [Full Text] [Related]

  • 28. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
    Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Hammel P, Rougier P.
    Am J Gastroenterol; 2000 Nov 15; 95(11):3276-81. PubMed ID: 11095353
    [Abstract] [Full Text] [Related]

  • 29. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
    Oberg K.
    Ann Oncol; 2001 Nov 15; 12 Suppl 2():S111-4. PubMed ID: 11762335
    [Abstract] [Full Text] [Related]

  • 30. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M, Gussoni G, Cuttica CM, Giordano G.
    J Clin Endocrinol Metab; 1996 Jun 15; 81(6):2089-97. PubMed ID: 8964833
    [Abstract] [Full Text] [Related]

  • 31. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
    Krassas GE, Doumas A, Kaltsas T, Halkias A, Pontikides N.
    Thyroid; 1999 Jan 15; 9(1):47-52. PubMed ID: 10037076
    [Abstract] [Full Text] [Related]

  • 32. Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone.
    Ito J, Sekiya M, Miura K, Yoshimi K, Suzuki T, Seyama K, Izumi H, Uekusa T, Takahashi K.
    Intern Med; 2009 Jan 15; 48(12):1061-4. PubMed ID: 19525599
    [Abstract] [Full Text] [Related]

  • 33. Clinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumors.
    Paragliola RM, Prete A, Papi G, Torino F, Corsello A, Pontecorvi A, Corsello SM.
    Drug Des Devel Ther; 2016 Jan 15; 10():3459-3470. PubMed ID: 27822010
    [Abstract] [Full Text] [Related]

  • 34. The safety of lanreotide for neuroendocrine tumor.
    Godara A, Siddiqui NS, Byrne MM, Saif MW.
    Expert Opin Drug Saf; 2019 Jan 15; 18(1):1-10. PubMed ID: 30582380
    [Abstract] [Full Text] [Related]

  • 35. [The role of somatostatin analogues in the treatment of hypophyseal adenomas].
    Losa M, Mortini P, Giovanelli M.
    Minerva Endocrinol; 2003 Mar 15; 28(1):39-51. PubMed ID: 12621362
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetic evaluation of lanreotide.
    Hu M, Tomlinson B.
    Expert Opin Drug Metab Toxicol; 2010 Oct 15; 6(10):1301-12. PubMed ID: 20716034
    [Abstract] [Full Text] [Related]

  • 37. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
    Cives M, Strosberg J.
    Drugs; 2015 May 15; 75(8):847-58. PubMed ID: 25911185
    [Abstract] [Full Text] [Related]

  • 38. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
    O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P.
    Cancer; 2000 Feb 15; 88(4):770-6. PubMed ID: 10679645
    [Abstract] [Full Text] [Related]

  • 39. Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma.
    Vainas I, Koussis Ch, Pazaitou-Panayiotou K, Drimonitis A, Chrisoulidou A, Iakovou I, Boudina M, Kaprara A, Maladaki A.
    J Exp Clin Cancer Res; 2004 Dec 15; 23(4):549-59. PubMed ID: 15743023
    [Abstract] [Full Text] [Related]

  • 40. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
    Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L.
    Cancer; 2006 Nov 15; 107(10):2474-81. PubMed ID: 17054107
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.